Serum endotrophin identifies optimal responders to PPAR[gamma] agonists in type 2 diabetes

Aims/hypothesis The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the [alpha]3 chain of...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2017-01, Vol.60 (1), p.50
Main Authors: Karsdal, Morten A, Henriksen, Kim, Genovese, Federica, Leeming, Diana J, Nielsen, Mette J, Riis, Bente J, Christiansen, Claus, Byrjalsen, Inger, Schuppan, Detlef
Format: Article
Language:English
Subjects:
Angiogenesis
Ballet
Body fat
Collagen
Diabetes
Edema
Glucagon
Glucose
Heart failure
Insulin resistance
Metabolism
Peptides
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis The treatment of type 2 diabetes with full peroxisome proliferator-activated receptor gamma (PPARγ) agonists improves insulin sensitivity, but is associated with weight gain, heart failure, peripheral oedema and bone loss. Endotrophin, the C-terminal fragment of the [alpha]3 chain of procollagen type VI (also called Pro-C6), is involved in both adipose tissue matrix remodelling and metabolic control. We established a serum assay for endotrophin to assess if this novel adipokine could identify type 2 diabetic patients who respond optimally to PPARγ agonists, improving the risk-to-benefit ratio. Methods The BALLET trial (NCT00515632) compared the glucose-lowering effects and safety of the partial PPARγ agonist balaglitazone with those of pioglitazone in individuals with type 2 diabetes on stable insulin therapy. The per protocol population (n=297) was stratified into tertiles based on baseline endotrophin levels. Participants were followed-up after 26 weeks, after which correlational analysis was carried out between endotrophin levels and measures of glucose control. This is a secondary post hoc analysis. Results Endotrophin was significantly associated with therapeutic response to balaglitazone and pioglitazone. At week 26, only individuals in the upper two tertiles showed significant reductions in HbA1c and fasting serum glucose compared with baseline. The OR for a 1% and a 0.5% reduction in HbA1c for individuals in the upper two tertiles were 3.83 (95% CI 1.62, 9.04) p
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-016-4094-1